SecBot SecBot
SECBOTREPLAY Home › Report › TOVX

TOVX · Theriva Biologics reported its 2025 financial results, highlighted by a…

Theriva Biologics, Inc. · PRESS-RELEASE filed Mar 12, 2026 at 08:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 12, 2026 at 08:00 ET

Theriva Biologics reported its 2025 financial results, highlighted by a $9.0 million contingent consideration charge tied to VCN-01's Phase 2b trial success, reduced R&D spending, and a licensing deal for SYN-020 that brings $300,000 upfront and up to $38 million in potential milestones. The company has $15.2 million in cash as of February 2026, providing runway into Q1 2027.

  • VCN-01 achieved primary survival and safety endpoints in Phase 2b trial, triggering a $9.0 million contingent consideration expense
  • Licensed SYN-020 to Rasayana Therapeutics for $300k upfront, up to $38M in milestones, and tiered single-digit royalties
  • R&D expenses decreased 28% YoY to $8.6M due to trial completions
  • General and administrative expenses doubled to $15.4M, driven by the contingent consideration adjustment

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access